Selective matrix metalloproteinase inhibition with developing heart failure: Effects on left ventricular function and structure

Circulation Research

Volumn 92, Issue 2, 2003, Pages 177-185

  King, Mary K ^a   Coker, Mytsi L ^a   Goldberg, Aaron ^a   McElmurray III, James H ^a   Gunasinghe, Himali R ^a   Mukherjee, Rupak ^a   Zile, Michael R ^a   O'Neill, Timothy P ^b   Spinale, Francis G ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Procter and Gamble   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart failure; Left ventricular systolic function; Matrix metalloproteinases; Myocardial stiffness; Myocardial structure

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; ENZYME INHIBITION; HEART LEFT VENTRICLE FUNCTION; HEART PRELOAD; HEART WORK; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; STRESS; SWINE;

ANIMALS; CARDIAC PACING, ARTIFICIAL; DIASTOLE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MYOCARDIUM; NEUROTRANSMITTER AGENTS; SWINE; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 0037423614     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000052312.41419.55     Document Type: Article

References (23)

1. Woessner JF, Nagase H. Introduction to the matrix metalloproteinases (MMPs). In: Matrix metalloproteinases and TIMPS. Oxford, UK: Oxford University Press; 2000:1-125.
2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
3. Nelson AR, Fingleton B, Rathenberg ML, Matrisian LM. Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol. 2000;18:1135-1149.
4. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482-495.
5. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210.
6. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102: 1944-1949.
7. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99: 3063-3070.
8. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TMA, Coker ML, Etoh T, Spinale FG. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001;103:2303-2309.
9. Spinale FG, Krombach RS, Coker ML, Mukherjee R, Thomas CV, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT. Matrix metalloproteinase inhibition during developing congestive heart failure: effects on left ventricular geometry and function. Circ Res. 1999;85:364-376.
10. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJH, Huxley P, Laber D, McCourt M, Whittaker M, Wood LM, Wright A. Preclinical and clinical studies of MMP inhibitors in cancer. N Y Acad Sci. 1999;878:228-235.
11. Peterson JT, Hua L. Matrix metalloproteinase inhibitor development for the treatment of heart failure. Drug Devel Res. 2002;55:29-44.
12. Levitt NC, Eskens FALM, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harrise AL, Verwiej J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res. 2001;7:1912-1922.
13. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46:214-234.
14. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in failing human heart. Circulation. 1998;98:1728-1734.
15. Pikul S, McDow Dunham KLM, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. J Med Chem. 1998;42:87-94.
16. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO, Tyson GS, Sabiston DC Jr, Rankin JS. Linearity of the Frank-Starling relationship in the intact heart: the concept of pre-load recruitable stroke work. Circulation. 1985;71:994-1009.
17. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass and function during development and regression of supraventricular tachycardia induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation. 1991;83:635-644.
18. Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PA. Cellular and extracellular remodeling with the development and recovery from tachycardia induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity, and proteoglycans. J Mol Cell Cardiol. 1996; 28:1591-1608.
19. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;15:753-758.
20. Onodera T, Tamura T, Said S, McCune SA, Gerdes AM. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension. 1998;32:753-757.
21. Boudreau N, Bissell MJ. Extracellular matrix signalling: integration of form and function in normal and malignant cells. Curr Opinion Cell Biol. 1998;10:640-646.
22. Ross RS, Borg TK. Integrins and the myocardium. Circ Res. 2001;8:88: 1112-1119.
23. 1 integrins are critical for fetal ventricular myocyte proliferation. Circ Res. 2000;15:87:508-515.